Podcasts about cancer screenings

Have no fear! Lizz and Moji are BACK this week and bringing you a big beautiful breakdown of all the ways the Big Bullshit Bill is coming for our abortion rights, even when abortion isn't explicitly mentioned… because why not be as sneaky as possible, amirite? AND we spill the tea on this week's crop of anti-abortion schemes to ruin our reproductive lives.  GUEST ROLL CALL!FBK bestie Pamela Merritt, Executive Director of Medical Students for Choice, is in the house to talk about what demonizing DEI and closing rural hospitals means for med students and overall healthcare disparities. Spoiler alert: it ain't great. PLUS!! Here to lift our pro-abort spirits is none other than Iranian and Muslim political comedian and host of the Fake The Nation pod, Negin Farsad!! She yaps with us on what brings her joy, staying positive, and fighting TF back. You won't want to miss Negin lay out exactly what's got her boob sweat boiling these days! Scared? Got questions about the continued assault on your reproductive rights? THE FBK LINES ARE OPEN! Just call or text (201) 574-7402, leave your questions or concerns, and Lizz and Moji will pick a few to address on the pod! Times are heavy, but knowledge is power, y'all. We gotchu.  SAVE THE DATE: OPERATION SAVE ABORTION: Sign up for virtual 2025 OSA workshop on August 9th! You can still join the 10,000+ womb warriors fighting the patriarchy by listening to our past Operation Save Abortion pod series and Mifepristone Panel by clicking HERE for episodes, your toolkit, marching orders, and more. HOSTS:Lizz Winstead IG: @LizzWinstead Bluesky: @LizzWinstead.bsky.socialMoji Alawode-El IG: @Mojilocks Bluesky: @Mojilocks.bsky.social SPECIAL GUESTS:Pamela Merritt IG/Threads: @PamelaMerritt_Sharkfu Bluesky: @Sharkfu.bsky.social Substack: @SharkfuNegin Farsad IG/TikTok/Patreon/Youtube: @NeginFarsad Bluesky: ‪@NeginFarsad.bsky.social‬ GUEST LINKS:Medical Students for Choice Website IG/TikTok: @MSFChoice Bluesky: @MSFChoice.bsky.social‬DONATE: Medical Students for ChoiceNegin Farsad WebsiteNegin Farsad LinktreeREAD: Negin's Column in The Progressive MagazinePODCAST: Fake the Nation NEWS DUMP:Texas Court Overturns Biden Administration's Expansion of Abortion PrivacyMan Goes in for a Vasectomy & This Is the Pamphlet He's GivenNew Book Confirms Trump Avoided Abortion Stance Because He Knew He'd LoseWith Trump's “One Big Beautiful Bill,” Congress Traded Your Pap Smear for a Billionaire's Tax BreakJudge Temporarily Blocks Trump Administration From Enforcing Funding Ban Against Planned ParenthoodExplaining Cost-Sharing Reductions and Silver Loading in ACA MarketplacesLISTEN: FBK Episode on Medina v Planned Parenthood Case EPISODE LINKS:TICKETS: Netroots Nations in New Orleans (use the code “BUZZKILLS” for 10% off)SIGN UP 8/9: (VIRTUAL) Operation Save Abortion at Netroots 2025 Our Amazing Moji in Nigeria6 DEGREES: The “Wednesday” Season 2, Part 1 TrailerJack Nicholson is Anti-AbortionBUY AAF MERCH!Operation Save AbortionSIGN: Repeal the Comstock ActEMAIL your abobo questions to The Feminist BuzzkillsAAF's Abortion-Themed Rage Playlist SHOULD I BE SCARED? Text or call us with the abortion news that is scaring you: (201) 574-7402 FOLLOW US:Listen to us ~ FBK Podcast Instagram ~ @AbortionFrontBluesky ~ @AbortionFrontTikTok ~ @AbortionFrontFacebook ~ @AbortionFrontYouTube ~ @AbortionAccessFront TALK TO THE CHARLEY BOT FOR ABOBO OPTIONS & RESOURCES HERE!PATREON HERE! Support our work, get exclusive merch and more! DONATE TO AAF HERE!ACTIVIST CALENDAR HERE!VOLUNTEER WITH US HERE!ADOPT-A-CLINIC HERE!EXPOSE FAKE CLINICS HERE!GET ABOBO PILLS FROM PLAN C PILLS HERE! When BS is poppin', we pop off!

Stephanie K and Jay welcome Crystal Dillard to the studio.  Crystal is from Buckham Alley Theatre which is Flint's only alternative theatre.  

Inilunsad ng pamahalaang nitong July 1 ang bagong screening program na layong matukoy ang mga kaso ng lung cancer nang mas maaga, lalo na sa mga taong may mataas na panganib, kabilang ang mga Indigenous Australians at ilang migranteng grupo.

A new national lung cancer screening program has been launched on 1 July which is aimed at detecting lung cancer in its early stages. In this SBS Hindi podcast, medical oncologist Dr Darshit A Thaker explains the key aspects of the program and shares important insights into lung cancer awareness, prevention and early detection.

Australians at higher risk of lung cancer are being urged to take advantage of a new screening program that has launched this month. The scan will be free for patients under Medicare bulk-billing through GPs, with eligibility to be determined by age - those between 50 and 70 - and smoking history. It is the first new national cancer screening program in nearly 20 years. Lung cancer is Australia's fifth most diagnosed cancer, but causes the greatest number of cancer deaths because it is often diagnosed too late. SBS's Biwa Kwan spoke with Anita Dessaix from the Cancer Council, about the at-risk groups the program is targeting; and the goal to prevent over 12,000 deaths over a decade

“The five-year relative survival rate for localized, or cancer that is confined to the colon or the rectum, is 91% for colon cancer and 90% for rectal cancer. Distant, metastasized to other organs—the five-year survival rate is 13% for colon and 18% for rectal cancer. So that really shows you the huge difference in screening and where screening can come in and make better outcomes,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer screening. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 4, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Leaners will report an increase in knowledge related to colorectal screening, early detection, and disparities. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episode: Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: AI-Assisted Colonoscopy Can Detect Small Colon Polyps As Colorectal Cancer Incidence Increases in Younger Patients, USPSTF Issues New Screening Guidelines. Here's How Nurses Can Encourage Uptake Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Text Messaging Reduces Disparities in Colorectal Cancer Screening USPSTF Recommends Colorectal Cancer Screening Should Begin at 45 Clinical Journal of Oncology Nursing articles: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Colorectal Cancer Screening: A Quality Improvement Initiative Using a Bilingual Patient Navigator, Mobile Technology, and Fecal Immunochemical Testing to Engage Hispanic Adults Oncology Nursing Forum article: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data ONS Course: Prevention, Detection, and the Science of Cancer—Oncology RN ONS Biomarker Database ONS Colorectal Cancer Learning Library American Cancer Society colorectal cancer resources Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Interestingly, recent studies suggest that starting screening even earlier than 45, such as age 40, could significantly reduce mortality and incidence rates, especially as colorectal cancer is rising among younger adults.” TS 2:42 “[Artificial intelligence]-enhanced screening tools are also being developed to improve sensitivity, reduce turnaround time, and enable real-time monitoring of disease progression. These innovations aim to make screening more accessible and accurate, especially in our underserved populations. So there's a huge impact on early detection.” TS 4:07 “Those with multiple chronic conditions or limited mobility may be less likely to complete screening, and those results may be harder to interpret. I mentioned a little bit earlier about our underserved or minority populations. Those barriers such as limited health literacy, lack of insurance, and cultural stigma can reduce screening uptake and ultimately follow-through.” TS 12:25 “Patient navigation programs—this is where we have trained navigators to help patients schedule appointments, understand procedures, and ultimately overcome some of these logistical hurdles. These have actually been shown to significantly boost screening rates. Also, those mailed stool-based-test kits—sending those kits directly to a patient home, especially with a personalized letter from a provider to add that extra little touch, has proven effective in increasing participation.” TS 21:29 “Our screening can detect cancer before symptoms appear and even identify precancerous polyps, which can be removed to prevent cancer altogether. Studies actually show that regular screening can reduce colorectal cancer mortality by up to 35% and the incidence of advanced-stage disease by nearly 30%. Just another reason why screening really does matter.” TS 25:53 “Evaluating our implicit bias, especially in something as critical as colorectal cancer, requires both introspection and instructional supports. One way of doing this is by auditing your practice patterns, really looking at reviewing your own screening recommendations and follow-up rates across different patient demographics. So are there certain groups that are less likely to be offered a colonoscopy? I think some of us may have an implicit bias—you see a patient; you're like, ‘There's no way they're going to agree to that, so I'm just not going to offer it.' Where we don't offer it, they don't have that opportunity to decline that. That can lead to further delay. And those patterns can reveal a bias in action.” TS 28:18

In this episode of "Coaching Healthcare Leaders," Dr. Alexander Itskovitch, medical director of the State Ser Cancer Center, shares his journey from aspiring surgeon to healthcare executive, highlighting the importance of mentorship, team empowerment, and work-life balance. He discusses leveraging artificial intelligence to enhance patient care and emphasizes the importance of fostering a positive organizational culture. The conversation addresses physician burnout and the need for supportive leadership. Dr. Alexander's insights offer valuable lessons on fostering resilient healthcare teams and enhancing patient outcomes through collaboration, innovation, and prioritizing staff well-being. Introduction to the Podcast and Guest (00:00:02) Dr. Lisa introduces the podcast, its mission, and welcomes Dr. Alexander, highlighting his background and achievements. Dr. Alexander's Career Journey (00:02:16) Dr. Alexander shares his early interest in surgery, training path, mentorship, and progression into leadership roles. Transition to Medical Director Role (00:04:51) Dr. Alexander discusses the pivotal decision to move into an administrative leadership position at a community cancer center. Training Required for Hepatobiliary Surgery (00:05:31) Explanation of the educational and training pathway to become a hepatobiliary surgeon, emphasizing mentorship and apprenticeship. Importance of Mentorship in Medicine (00:06:41) Discussion on the critical role of mentorship in medical training and ongoing professional development. A Day in the Life of a Medical Director (00:08:09) Dr. Alexander describes balancing clinical and administrative duties, weekly schedule, and responsibilities as a cancer center director. Impacting the Community Through Cancer Care (00:10:22) Exploration of how cancer screening, prevention, and high-risk programs benefit the local community. Challenges in Cancer Screening and Follow-Up (00:12:45) Addressing logistical and socioeconomic barriers to effective cancer screening and follow-up, and their impact on outcomes and costs. Information Overload and Integration in Healthcare (00:15:02) Challenges of managing vast medical information, the need for better integration, and the potential of AI to assist. Artificial Intelligence in Cancer Care (00:16:41) Examples of AI implementation to track incidental findings and improve patient safety and follow-up. Barriers to AI Adoption in Health Systems (00:18:28) Discussion on IT limitations, need for expertise, and bridging the gap between IT and clinical teams for AI adoption. Leadership and Team Management Philosophy (00:20:26) Dr. Alexander shares his leadership style, focus on culture, empowering team members, and hiring for fit and excellence. Empowering Teams and Achieving Success (00:23:10) Anecdotes about hiring strong team members, their impact on clinical trial enrollment, and the motivation derived from a great team. Work-Life Balance and Physician Well-being (00:24:19)- Strategies for Maintaining Personal Well-being, Setting Boundaries, and Encouraging Staff to Prioritize Self-Care. Leadership Responsibility and Staff Consideration (00:26:20) Emphasizes the leader's role in considering staff well-being, preventing burnout, and making thoughtful administrative decisions. Conclusion and Appreciation (00:27:15) Dr. Lisa thanks Dr. Alexander for sharing his journey and insights, closing the episode. Follow Dr. Itskovitch on LinkedIn

Dr. Joe Sirven and his team of medical experts discuss this month's biggest health headlines, from brain-eating amoebas to at-home test kits for cervical cancer.

If doctors can catch breast cancer early enough, the chances of survival are about 90%. In order to catch it early enough, women over the age of 40 usually get annual mammograms, paid for by their health insurance. Roughly half of those women have dense breast tissue that requires additional screenings, however, which aren't always covered by insurance. Also: a record-high stock market and the state of the economy surrounding the Strait of Hormuz.

If doctors can catch breast cancer early enough, the chances of survival are about 90%. In order to catch it early enough, women over the age of 40 usually get annual mammograms, paid for by their health insurance. Roughly half of those women have dense breast tissue that requires additional screenings, however, which aren't always covered by insurance. Also: a record-high stock market and the state of the economy surrounding the Strait of Hormuz.

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

In this Healthed lecture, Dr Tracy Leong brings GPs up to speed on the National Lung Cancer Screening Program that will commence on July 1, 2025.See omnystudio.com/listener for privacy information.

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV - The LGBTQI+ Community's Disproportionate Cancer Burden - Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers - Barriers to Health Care Access, Including Discrimination - Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housing, Gay Men & Lesbian Cancer Issues - Transgender/Gender-Nonconforming People's Cancer Concerns - Challenges for LGBTQI+ Caregivers - Social Security Disability Benefits for LGBTQI+ People Living with Cancer - Military Service & the LGBTQI+ Community - Practical, Financial, Emotional & Social Concerns - Cancer Resources for the LGBTQI+ Community - Questions to Ask Our Panel of Experts

Today we are joined by Dr Brandon Baraty and Associate Professor Viraj Kariyawasam, two leading experts in gastroenterology, to discuss the latest in inflammatory bowel disease (IBD) management and bowel cancer screening. They'll share insights into the most recent advancements in diagnostic techniques and cutting-edge treatment options shaping the future of patient care.This podcast is sponsored by Macquarie University Hospital, part of MQ Health - a trailblazer in healthcare, education and research.Dr Baraty is a senior Gastroenterologist, Hepatologist, and Endoscopist. He is the Head of Discipline of Gastroenterology at Macquarie University Hospital and the Director of Endoscopy at Ryde Hospital. Dr Baraty specialises in IBD care and is a leading expert in transabdominal ultrasound for IBD assessment in New South Wales.Associate Professor Kariyawasam is a Senior Gastroenterologist, Hepatologist, and Endoscopist at Macquarie University Hospital and Concord Hospital. He holds a PhD from Sydney University and has completed international fellowship training in IBD. He is dedicated to advancing IBD diagnosis and management while actively supporting patient advocacy and education.

Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Yankees offering free skin cancer screening To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Prostate cancer screening isn't just clinical—it's personal. Especially when headlines make it political.In this episode Tracy breaks down the buzz around President Joe Biden's recent prostate cancer diagnosis—and uses the moment to teach, clarify, and contextualize what it really means to screen for prostate cancer in 2025.As a former Urology PA, Tracy brings her clinical experience and clear communication to an often-misunderstood topic. She walks through:What the prostate does and how PSA testing worksWhat elevates PSA levels (that isn't cancer)Why BPH complicates the pictureWhat Gleason scores tell us about cancer aggressivenessCurrent USPSTF and AUA guidelines for prostate cancer screeningHow shared decision-making, not headlines, should guide patient careThis episode is a reminder to return to nuance and individualize care—especially when the world is watching.

The rhetoric and violence are both escalating on all sides in the Iran-Israel war. U.S. President Donald Trump is now demanding Iran's unconditional surrender, while appearing to threaten the country's supreme leader. Iran and Israel are firing missiles at each other. And Israeli Prime Minister Benjamin Netanyahu hints at regime change – in Iran.Also: Mark Carney is trying to make the most of what's left of the G7 in Alberta. The leaders kept their meetings going without the most consequential member: Trump. The U.S. president left last night – one day ahead of schedule. Even without him, leaders are focused on delivering more help to Ukraine and putting more pressure on Russia.And: New warnings about colorectal cancer. More young people are being diagnosed with it – and advocacy groups are calling for screening at a younger age.Plus: Indigenous groups protest the One Canadian Economy bill, 23andme fails to protect privacy, and more.

In this episode, Dr. Paul Wheatley-Price and Dr. Renelle Myers discuss all there is to know about lung cancer screening in 2025 - what is lung cancer screening and why is it important, who can get screened, where it's available, and the latest technologies and advances in screening. Dr. Myers is an Interventional Pulmonologist and Clinician-Scientist at BC Cancer, and Clinical Associate Professor at the University of British Columbia.

In this episode, Dayna Johnson discusses the importance of oral cancer screening as part of the oral health indicators outlined in the FDI and Henry Schein Electronic Health Records Project. She emphasizes the alarming statistics regarding screening rates and the need for better documentation in dental practices. Additionally, she provides insights on how to bill for oral cancer screenings and the significance of using diagnostic codes to improve data collection and patient care. Takeaways ➡Oral cancer screening is a critical health indicator. ➡60% of residents in North Carolina are not screened. ➡Documentation of oral cancer screenings is often lacking. ➡AI tools can streamline clinical documentation. ➡Billing codes exist for oral cancer screenings now. ➡Insurance companies may resist paying for screenings. ➡Using diagnostic codes can improve billing success. ➡Data collection is essential for improving health outcomes. ➡Practices should share information with colleagues. ➡Continuous education is vital for dental professionals. Chapters 00:00 Introduction to Oral Health Indicators 01:28 Focus on Oral Cancer Screening 04:21 The Importance of Documentation 09:32 Billing for Oral Cancer Screenings 17:24 Conclusion and Next Steps Please rate, review and share this episode with your colleagues. Book a call with Dayna: https://calendly.com/dayna-johnson/discovery-call

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from May 31-June 6, 2025.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/KDS865. CME/MOC/AAPA credit will be available until June 6, 2026.Facilitating Progress in Early Detection & Intervention in Lung Cancer: Proactive Strategies to Improve Lung Cancer Screening for High-Risk Individuals in VA Healthcare Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Association of Veterans' Research and Education Foundations. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

In this episode we are exploring two publications related to cancer care. In our first segment we talk to 2 authors about their research on genetic counselors and identification of patients for high-risk pancreatic cancer screening. In our second segment, Khalida interviews a genetic counselor about their study to evaluate surgical patient perspectives of genetic testing provided by a non-genetics professional.  Segment 1: “Practices and perspectives of genetic counselors about high-risk pancreatic cancer screening: A cross-sectional survey study” Amy Wiegand is a board-certified genetic counselor who specializes in cancer genetics. She graduated with her Master's in Genetic Counseling in 2017 from from the Icahn School of Medicine at Mount Sinai and has worked as a cancer genetic counselor at the Smilow Cancer Genetics and Prevention Program at Yale-New Haven Health since 2017 where she has seen over 2500 patients for a variety of hereditary cancer indications. Her research interests include hereditary pancreatic cancer and alternative delivery care models for genetic testing. Aparna is a senior genetic counseling assistant (GCA) at Smilow Cancer Genetics and Prevention Program at Yale New Haven Health where she has worked since 2019, and she has over 6 years of experience as a GCA. She holds a Master's degree in Biomedical Genetics and a Bachelor's degree in Biotechnology. She also has a varied background in administration, finance and customer service. She is a high-performing individual and was recently recognized by her colleagues as ‘Employee of the Quarter' and honored by the organization as ‘Smilow Star' for consistently going above and beyond for the patients and the co-workers and for exemplifying the health system's values. She contributes to the program in a variety of other ways outside of her role and works collaboratively with the team to create a patient centered environment. She has a strong interest in Cancer Genetics and is passionate about research. She is currently working on another research project, the abstract of which was selected for presentation in a Poster Session at 2025 ASCO (American Society of Clinical Oncology) annual meeting. She enjoys being part of a collaborative and dynamic team at Smilow Cancer Genetics and Prevention program and is excited about the upcoming research initiatives in the program. In this segment we discuss: - The significance of pancreatic cancer surveillance for high-risk individuals and why early detection plays a critical role in improving outcomes. - How genetic counselors are uniquely positioned to identify and refer individuals at high risk for pancreatic cancer, emphasizing their role in screening efforts. - An overview of the 2019 CAPS (Cancer of the Pancreas Screening) consensus guidelines and how they are applied to identify high-risk individuals for surveillance - The finding that nearly 70% of genetic counselors accurately identified individuals eligible for screening and discussed the factors that may have contributed to this high rate. - The association between provider comfort level and accuracy in identifying high-risk individuals, and discussed strategies to improve provider confidence and access to screening programs.   Segment 2: “Patient experiences of cancer genetic testing by non-genetics providers in the surgical setting” Katie Fiallos is a board-certified genetic counselor who earned her Master of Science in Genetic Counseling from the Johns Hopkins University/National Human Genome Research Institute Genetic Counseling Training program in 2017 and worked for seven years as a cancer genetic counselor at Johns Hopkins. She joined the Department of Medical and Molecular Genetics at Indiana University in August 2024. She is fluent in Spanish and provides genetic counseling in English and Spanish to participants with Parkinson's disease enrolled in the PD GENEration study. She has authored several academic papers related to genetic counseling, and her current research interests include provision of genetic counseling to Latine individuals, alternate service delivery models, and patient experiences with genetic testing and their informational desires. She lives in Michigan with her family and enjoys staying active, particularly practicing aerial silks. The research for the paper we're discussing was done while she was at Johns Hopkins and was funded by the Jennifer L. Brager Memorial Research award through the Johns Hopkins Kimmel Cancer Center.   In this segment we discuss: - Why hereditary cancer genetic testing is becoming increasingly important for patients with breast cancer, especially in relation to surgical decision-making. - The findings that patients preferred genetic testing at an existing appointment shortly after diagnosis, and explored how this timing affects their overall experience. - How many patients had already considered or wanted genetic testing before it was offered, shedding light on patient awareness and readiness. - Why patients were primarily motivated by concern for relatives and a desire for complete information, rather than surgical decision-making. - Gaps in patient-provider communication identified in the study and suggested ways for providers to address these issues in clinical practice.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.

Jarvis Greer - Memphis Icon/Sports HoFer - with J&J Show on the June 7th Free Cancer Screening Event AND TIGER FOOTBALL EXPECTATIONS

My guest is Dr. Mark Hyman, M.D., a physician and world leader in the field of functional medicine. We discuss a systems-based framework for diagnosing and treating the root causes of disease, rather than simply managing symptoms. We also cover cutting-edge health and longevity tools such as peptides, NAD/NMN, exosomes, proactive blood testing and cancer screening, as well as nutrition, supplementation, detoxification, and strategies for addressing specific diseases and health challenges. This discussion will benefit anyone seeking to improve their vitality or combat specific health concerns. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman ROKA: https://roka.com/huberman Timestamps 00:00:00 Dr. Mark Hyman 00:01:48 Functional Medicine, Chronic Fatigue Syndrome, Mercury; Systems Medicine 00:08:51 Metabolic Psychiatry; Medicine, Creating Health vs Treating Disease 00:12:19 Sponsors: Joovv & Eight Sleep 00:15:06 Wholistic View of Body, Root Causes 00:19:48 Medicine & Research; “Exposome”, Impediments & Ingredients for Health, Whole Foods 00:26:30 Seed Oils, Starch & Sugar, Ultra-Processed Foods; Obesity Rise 00:36:27 Sponsors: Function & ROKA 00:40:05 Tool: Ingredients for Health, Personalization; Multimodal Approach 00:46:25 Essential Supplements, Omega-3s, Vitamin D3, Multivitamin, Iodine, Methylated B12 00:56:54 Supplements & Traditional Medicine; Limited Budget & Nutrition 01:02:54 Air, Tool: Air Filters; Tap Water Filter; Tool: Health, Expense & Whole Foods 01:09:03 Food Industrialization, Processed Foods 01:14:23 Sponsor: AG1 01:16:18 Declining American Health & Nutrition, Politics, MAHA 01:26:03 Toxins, Food Additives, Generally Recognized As Safe (GRAS) 01:29:25 SNAP Program & Soda, Food Industry & Lobbying 01:36:58 Big Food, Company Consolidation, Nutrition Labels 01:44:21 GLP-1 Agonists, Doses, Risks; Food as Medicine, Ketogenic Diet 01:51:29 Cancer, Diets & Alcohol 01:54:03 Blood Markers, ApoB, Cholesterol, Tool: Test Don't Guess, Individualization 02:02:54 Mercury; Tool: Detoxification, Sulforaphane, N-Acetylcysteine (NAC) 02:04:56 Endocrine Disrupting Chemicals, Fertility, Tool: Hormone Panels; Heavy Metals 02:11:36 Upregulate Detox Pathways, Gut Cleanse, Tools: Cilantro Juice, Fiber 02:17:08 Peptides, PT-141 (Vyleesi), BPC-157, Thymosin Alpha-1; Risks, Cycling 02:22:03 Cancer Screening, Data & Personalized Health; Alzheimer's Disease 02:30:45 Longevity Switches, NAD, NMN; Exosomes, Stem Cells 02:39:50 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures